← back to search

Nadeem R. Abu‐Rustum

Memorial Sloan Kettering Cancer Center · US
Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Cervical Cancer and HPV Research, and Uterine Myomas and Treatments.
h-index
91
citations
33,841
works
834
NIH funding
primary concept
Medicine
email

Recent publications

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Journal of the National Comprehensive Cancer Network 2025cited by 36position: firstdoi
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer
Nature 2025cited by 31position: middledoi
Artificial intelligence in the diagnosis and management of gynecologic cancer
International Journal of Gynecology & Obstetrics 2025cited by 19position: middledoi
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network 2025cited by 7position: firstdoi
Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract
Modern Pathology 2025cited by 4position: middledoi
A Feasibility Study for Mapping Ovarian Sentinel Lymph Nodes
Obstetrics and Gynecology 2025cited by 4position: middledoi
Evaluation of survival and mortality in pelvic exenteration for gynecologic malignancies: a systematic review, meta-analyses, and meta-regression study
International Journal of Gynecological Cancer 2025cited by 4position: middledoi
Trachelectomy and Cerclage Placement as Fertility-Sparing Surgery for Cervical Cancer-An Expert Survey.
2025cited by 3position: contributordoi
Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level.
2025cited by 1position: contributordoi
Supplementary Figure S2 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Figure S3 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Table S3 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Figure S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Figure S5 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Figure S1 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Table S2 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Supplementary Table S1 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Data from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
2025cited by 0position: contributordoi
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2024cited by 78position: firstdoi
Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis
Gynecologic Oncology 2024cited by 34position: middledoi
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
International Journal of Gynecological Cancer 2024cited by 31position: middledoi
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study.
2024cited by 20position: contributordoi
Consensus on surgical technique for sentinel lymph node dissection in cervical cancer.
2024cited by 18position: contributordoi
Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation
International Journal of Gynecological Cancer 2024cited by 13position: middledoi
Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification
Gynecologic Oncology 2024cited by 13position: middledoi
Establishing guidelines for sentinel lymph node ultrastaging in endometrial cancer.
2024cited by 8position: contributordoi
Assessing minimally invasive simple hysterectomy in low risk cervical cancer: set up for the LASH trial.
2024cited by 8position: contributordoi
Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation.
2024cited by 7position: contributordoi
Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer.
2024cited by 6position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 40 papers (2021–2025)Mario M. Leitão · Memorial Sloan Kettering Cancer Center29 papers (2013–2024)Alexia Iasonos · Repsol (Spain)21 papers (2013–2025)Ginger J. Gardner · Henry Ford Hospital16 papers (2013–2025)Robert A. Soslow · Cleveland Clinic16 papers (2013–2023)Arnaud Da Cruz Paula · Universidade do Porto16 papers (2023–2025)Britta Weigelt · New York University16 papers (2023–2025)Pier Selenica · New York University16 papers (2023–2025)Jennifer J. Mueller · Memorial Sloan Kettering Cancer Center15 papers (2016–2025)S. Dennis · Twitter (United States)15 papers (2012–2025)Lora H. Ellenson · Memorial Sloan Kettering Cancer Center13 papers (2020–2024)Qin Zhou · Memorial Sloan Kettering Cancer Center13 papers (2013–2024)Oliver Zivanovic · Gynecologic Oncology Group13 papers (2015–2025)Yukio Sonoda · University of Milano-Bicocca13 papers (2012–2021)Jorge S. Reis‐Filho · AstraZeneca (France)12 papers (2022–2025)Kaled M. Alektiar · Memorial Sloan Kettering Cancer Center11 papers (2013–2024)Shirin Issa Bhaloo · Kettering University11 papers (2025–2025)Nadeem Riaz · New York Oncology Hematology11 papers (2025–2025)Timothy Hoang · Kettering University11 papers (2025–2025)David N. Brown · Kettering University11 papers (2025–2025)